E2F1 promotes cell migration in hepatocellular carcinoma via FNDC3B

Kate Hua,Chen‐Tang Wu,Chin‐Hui Lin,Chian‐Feng Chen
DOI: https://doi.org/10.1002/2211-5463.13783
2024-02-26
FEBS Open Bio
Abstract:FNDC3B is highly expressed and involved in cell migration. To explore its regulation mechanism, we utilized bioinformatic, regulation, and DNA–protein interaction screening to investigate its upstream regulator from 338 candidates. Our results revealed that E2F1 binds to the promoter and modulates the expression and function of FNDC3B. These findings enhance our understanding of the regulatory mechanisms governing FNDC3B expression. FNDC3B (fibronectin type III domain containing 3B) is highly expressed in hepatocellular carcinoma (HCC) and other cancer types, and fusion genes involving FNDC3B have been identified in HCC and leukemia. Growing evidence suggests the significance of FNDC3B in tumorigenesis, particularly in cell migration and tumor metastasis. However, its regulatory mechanisms remain elusive. In this study, we employed bioinformatic, gene regulation, and protein‐DNA interaction screening to investigate the transcription factors (TFs) involved in regulating FNDC3B. Initially, 338 candidate TFs were selected based on previous chromatin immunoprecipitation (ChIP)‐seq experiments available in public domain databases. Through TF knockdown screening and ChIP coupled with Droplet Digital PCR assays, we identified that E2F1 (E2F transcription factor 1) is crucial for the activation of FNDC3B. Overexpression or knockdown of E2F1 significantly impacts the expression of FNDC3B. In conclusion, our study elucidated the mechanistic link between FNDC3B and E2F1. These findings contribute to a better understanding of FNDC3B in tumorigenesis and provide insights into potential therapeutic targets for cancer treatment.
biochemistry & molecular biology
What problem does this paper attempt to address?